Report Overview

The global gout therapeutics market size stood at around USD 2.4 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Gout is a common form of inflammatory arthritis. Gout is caused due to higher levels of uric acid in the blood. Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid. Additionally, factors such as diet containing red meat, obesity, and high consumption of alcohol can cause gout.
The global gout market is majorly driven by the increasing prevalence of obesity, rising older population leading to rise in the patient population, the rise in cigarette smoking population, and growing mass young population inclined towards a sedentary lifestyle. Additionally, factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market.



Market Drivers

Increasing number of regulatory approvals for anti-gout drugs is expected to propel growth of the global gout disease treatment market over the forecast period. For instance, in February 2019, ROMEG Therapeutics received the U.S. FDA approval for Gloperba, a colchicine oral solution 0.6mg/5 ml. It is the first oral liquid solution of colchicine approved by the U.S. FDA. The drug is developed to prevent or treat gout attack. Moreover, in December 2015, AstraZeneca received the U.S. FDA approval for ZURAMPIC (lesinurad) 200 mg tablets. The drug, in combination with a xanthine oxidase inhibitor (XOI), is indicated for the treatment of hyperuricemia associated with gout.

Increasing adoption of inorganic strategies such as collaboration by key players operating in the-pharmaceutical industry is expected to drive the gout disease treatment market growth. For instance, in September 2019, Simcere Pharmaceutical Group and JW Pharmaceutical entered into a collaboration and exclusive license agreement for the development of anti-gout drug candidate URC-102 in China. Moreover, in January 2019, Horizon Pharma plc and HemoShear Therapeutics, LLC entered into a collaboration agreement to develop novel therapeutics for gout.

Moreover, increasing number of pipeline products is expected to boost growth of the gout disease treatment market over the forecast period. For instance, in February 2017, the University of Alabama at Birmingham in collaboration with University of Auckland, New Zealand initiated phase 2 clinical trial to study the safety and efficacy of Denosumab, a fully human monoclonal antibody with a high affinity for RANKL, in addition to urate-lowering therapy (ULT), for the treatment of bone erosion associated with gout disease. This study is expected to be completed by February 2020. These factors are expected to drive growth of the gout disease treatment market over the forecast period.